Table 4.

Clinical outcome according to RASI therapy in patients with IMR

	Treatment		Univariate analysis		Multivariate analysis		IPTW
	RASI(+) (n=395)	RASI(−) (n=156)	Unadjusted (95% CI)	P value	Adjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
All-cause death	34 (9)	39 (25)	0.27(0.17 to 0.43)	<0.001	0.44(0.27 to 0.72)	0.001*	0.43(0.25 to 0.74)	0.002
Cardiac death	10 (3)	21 (13)	0.15(0.07 to 0.32)	<0.001	0.33(0.14 to 0.76)	0.009*	0.28(0.12 to 0.66)	0.004
Composite outcome†	29 (7)	31 (20)	0.30(0.18 to 0.50)	<0.001	0.53(0.30 to 0.92)	0.025‡	0.51(0.28 to 0.95)	0.033

*Covariates include peak CK, Killip classification, serum creatinine, prior MI, moderate/severe MR and β-blocker.

†Cardiac death or heart failure.

‡Adjusted with hypertension, peak CK, Killip classification, serum creatinine, prior MI, moderate/severe MR and β-blocker.

CK, creatine kinase; IMR, ischaemic mitral regurgitation; IPTW, Inverse probability of treatment weighted; MI, myocardial infarction; RASI, renin–angiotensin system inhibitor.